top of page

Response Pharmaceuticals

High-Resolution Microscopic View of Clinical-Stage Drug RDX-002
Photomicrograph of RDX-002

Response Pharmaceuticals, Inc.



Microsomal triglyceride transfer protein (MTP) is a protein that helps the body absorb and transport dietary fats and cholesterol. It is found in the cells of the liver and the lining of the small intestine. In the small intestine, MTP helps transport fat molecules from our food into the bloodstream. These fat molecules are then carried to other parts of the body, where they can be used for energy or stored as fat. MTP is vital to the body's dietary fat and cholesterol delivery network. Without MTP, it would be difficult for the body to absorb and use these essential nutrients.

(microsomal triglyceride transfer protein)


RDX-002 is a small molecule drug taken orally as a capsule or tablet. It is a very potent and highly specific compound that inhibits the ability of enterocytic microsomal triglyceride transfer protein (eMTP) to function correctly. eMTP is a protein that helps to transport triglycerides (fats) and cholesterol from the intestine to the rest of the body. 

The overall effect of eMTP inhibition is a decrease in the amount of triglycerides and cholesterol delivered to the body after a meal. Since fat represents dietary calories, the number of calories gained from a meal decreases. This decrease in caloric intake is expected to reduce weight gain in patients taking atypical antipsychotics.


Response Pharmaceuticals, Inc, is a clinical-stage therapeutic development company focused on developing treatments for weight management and metabolic disease. Our initial clinical focus is to help people taking antipsychotic medications for disabling mental illness combat weight gain and metabolic dysregulation that is endemic with these treatments.


Response is developing RDX-002 as an adjunctive therapy for patients taking first-line antipsychotic therapy. RDX-002 is a first-in-class potent and selective inhibitor of intestinal MTP.  The small-molecule compound has been in multiple Phase 1 and Phase 2 clinical trials including over 500 volunteer and patient subjects dosed for up to 90 days. In these studies, RDX-002 lowered post-prandial triglyceride levels, circulating levels of LDLc, and reduced weight. By addressing treatment-limiting side effects of atypical antipsychotics, we anticipate (subject to completion of successful development and further clinical trials) that RDX-002 will allow for much more widespread use of clozapine and olanzapine, as well as other effective but underutilized antipsychotics while reducing the burdens of non-compliance, weight gain, and long-term metabolic disease. Recently completed a Phase 1B trial with Olanzapine

bottom of page